Could a menopause drug harm the liver? A computer model offers clues.

When a new drug for menopause symptoms comes along, one of the first questions doctors ask is: how safe is it for the liver? Researchers used a sophisticated computer model to simulate how fezolinetant might affect different groups of people. They predicted that for healthy volunteers, the drug at standard doses wouldn't cause significant liver injury. But in a simulated group of people with metabolic syndrome-associated fatty liver disease (MAFLD), the model showed mild increases in a liver enzyme and predicted one rare, serious case of liver injury at higher doses. The model also suggested that a specific biological process might help protect against that serious case. It's crucial to remember this was a simulation—a high-tech prediction, not a result from actual people taking the drug. The findings from this model were used to inform discussions about which doses to test in the next stage of research. Later, real phase 3 clinical trials in people confirmed the drug's effectiveness and acceptable liver safety at the approved 45 mg dose.